Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017
Clinical characteristics of disseminated strongyloidiasis, the severest form of strongyloidiasis, are not well described. We conducted a retrospective, consecutive chart review of patients with disseminated strongyloidiasis admitted to Okinawa Chubu Hospital in Okinawa, Japan, during January 1975–De...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2020-03-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/26/3/19-0571_article |
| _version_ | 1818684137275392000 |
|---|---|
| author | Mitsuru Mukaigawara Masashi Narita Soichi Shiiki Yoshihiro Takayama Shunichi Takakura Tomokazu Kishaba |
| author_facet | Mitsuru Mukaigawara Masashi Narita Soichi Shiiki Yoshihiro Takayama Shunichi Takakura Tomokazu Kishaba |
| author_sort | Mitsuru Mukaigawara |
| collection | DOAJ |
| description | Clinical characteristics of disseminated strongyloidiasis, the severest form of strongyloidiasis, are not well described. We conducted a retrospective, consecutive chart review of patients with disseminated strongyloidiasis admitted to Okinawa Chubu Hospital in Okinawa, Japan, during January 1975–December 2017. The 70 patients were classified into 3 clinical phenotypes: dissemination (32 patients [45.7%]), occult dissemination with meningitis caused by enteric organisms (12 patients [17.1%]), and occult dissemination with culture-negative suppurative meningitis (26 patients [37.1%]). Associated mortality rates were 56.3%, 16.7%, and 11.5%, respectively, and sepsis occurred in 40.6%, 58.3%, and 11.5% of cases, respectively. Common symptoms included fever (52.9% of patients), headache (32.9%), and altered mental status (24.3%). Patients were treated with thiabendazole (before 2003) or ivermectin (after 2003). Our findings show that disseminated strongyloidiasis has clinical phenotypes in terms of severity and that identification of occult dissemination, a mild form with prominent neurologic manifestations, is lifesaving. |
| first_indexed | 2024-12-17T10:45:51Z |
| format | Article |
| id | doaj.art-f32ae62971424ec9a03b8945c5af2972 |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-17T10:45:51Z |
| publishDate | 2020-03-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-f32ae62971424ec9a03b8945c5af29722022-12-21T21:52:07ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592020-03-0126340140810.3201/eid2603.190571Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017Mitsuru MukaigawaraMasashi NaritaSoichi ShiikiYoshihiro TakayamaShunichi TakakuraTomokazu KishabaClinical characteristics of disseminated strongyloidiasis, the severest form of strongyloidiasis, are not well described. We conducted a retrospective, consecutive chart review of patients with disseminated strongyloidiasis admitted to Okinawa Chubu Hospital in Okinawa, Japan, during January 1975–December 2017. The 70 patients were classified into 3 clinical phenotypes: dissemination (32 patients [45.7%]), occult dissemination with meningitis caused by enteric organisms (12 patients [17.1%]), and occult dissemination with culture-negative suppurative meningitis (26 patients [37.1%]). Associated mortality rates were 56.3%, 16.7%, and 11.5%, respectively, and sepsis occurred in 40.6%, 58.3%, and 11.5% of cases, respectively. Common symptoms included fever (52.9% of patients), headache (32.9%), and altered mental status (24.3%). Patients were treated with thiabendazole (before 2003) or ivermectin (after 2003). Our findings show that disseminated strongyloidiasis has clinical phenotypes in terms of severity and that identification of occult dissemination, a mild form with prominent neurologic manifestations, is lifesaving.https://wwwnc.cdc.gov/eid/article/26/3/19-0571_articledisseminationstrongyloidiasishuman T-cell lymphotrophic virus type 1HTLV-1meningitisStrongyloides stercoralis |
| spellingShingle | Mitsuru Mukaigawara Masashi Narita Soichi Shiiki Yoshihiro Takayama Shunichi Takakura Tomokazu Kishaba Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017 Emerging Infectious Diseases dissemination strongyloidiasis human T-cell lymphotrophic virus type 1 HTLV-1 meningitis Strongyloides stercoralis |
| title | Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017 |
| title_full | Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017 |
| title_fullStr | Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017 |
| title_full_unstemmed | Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017 |
| title_short | Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975–2017 |
| title_sort | clinical characteristics of disseminated strongyloidiasis japan 1975 2017 |
| topic | dissemination strongyloidiasis human T-cell lymphotrophic virus type 1 HTLV-1 meningitis Strongyloides stercoralis |
| url | https://wwwnc.cdc.gov/eid/article/26/3/19-0571_article |
| work_keys_str_mv | AT mitsurumukaigawara clinicalcharacteristicsofdisseminatedstrongyloidiasisjapan19752017 AT masashinarita clinicalcharacteristicsofdisseminatedstrongyloidiasisjapan19752017 AT soichishiiki clinicalcharacteristicsofdisseminatedstrongyloidiasisjapan19752017 AT yoshihirotakayama clinicalcharacteristicsofdisseminatedstrongyloidiasisjapan19752017 AT shunichitakakura clinicalcharacteristicsofdisseminatedstrongyloidiasisjapan19752017 AT tomokazukishaba clinicalcharacteristicsofdisseminatedstrongyloidiasisjapan19752017 |